All In Biotech

Drug Trial Radar · NCT01265849

Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

Phase III Study of LI [Multikine®] Plus SOC (Surgery + Radiotherapy or Surgery + Concurrent Radiochemotherapy) in Subjects With Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate vs. SOC Only

Last checked: Nov 20, 2026Latest source record: Aug 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 928 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

928

Actual

Start

Dec 2010

Primary completion

May 15, 2020

Study completion Dec 4, 2020

Sponsor

Lead sponsor
CEL-SCI CorporationIndustry
Sponsor type
Industry
Collaborators
Teva Branded Pharmaceutical Products R&D, Inc.; Orient Europharma Co., Ltd.
First posted
Dec 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine whether LI administered in combination with cyclophosphamide, indomethacin and zinc in a multivitamin (CIZ) combination prior to standard of care therapy (surgery followed by radiotherapy or concurrent radiochemotherapy) is safe and will increase the overall survival of subjects with previously untreated locally advanced primary squamous cell carcinoma of the oral cavity or soft palate at a median of 3 to 5 years

Conditions

  • Squamous Cell Carcinoma of the Oral Cavity
  • Squamous Cell Carcinoma of the Soft Palate

Interventions

  • LIBiological

    LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m\^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.

  • CyclophosphamideDrug

    Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m\^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m\^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.

  • IndomethacinDrug

    One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.

  • ZincDietary supplement

    One capsule daily self administered beginning on day one of treatment with LI until one day before surgery

  • SurgeryProcedure

    Excise tumor and nodes

  • CisplatinDrug

    Cisplatin was administered 100mg/m\^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m\^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.

  • RadiotherapyRadiation

    Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m\^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From the date of treatment assignment to death or the last follow-up date. Maximum follow-up was approximately 113 months.
  2. OS in Low Risk SubjectsTime frame: From the date of treatment assignment to death or the last follow-up date. Maximum follow-up was approximately 113 months.

Locations

102 sites in 23 countries. Site status is shown where the registry gives one.

  • Simmons Cancer Institute at Southern Illinois University

    Springfield, Illinois

  • Henry Ford Health System Henry Ford Hospital

    Detroit, Michigan

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Medical College Of South Carolina MSC550

    Charleston, South Carolina

  • VA Puget Sound Healthcare System & University of WA

    Seattle, Washington

  • HNO-Klinik der medizinischen Universitat Graz

    Graz, Austria

  • Vitebsk Regional Oncology Dispensary

    Vitebsk, Belarus

  • N.N. Alexandrov Research Istitute of Oncology and Medical Radiology

    Lyasny, Minsk Oblast, Belarus

  • Clinical Center Banja Luka

    Banja Luka, Bosnia and Herzegovina

  • University Clinical Hospital Mostar

    Mostar, Bosnia and Herzegovina

  • Clinical Centre University of Sarejevo Clinic for ENT

    Sarajevo, Bosnia and Herzegovina

  • University Clinical Centre Tuzla

    Trnovac, Tuzla, Bosnia and Herzegovina

  • CHU de Quebec - L'Hotel Dieu de Quebec

    Québec, Canada

  • St. Josephs Healthcare Department of Surgery

    Hamilton, Ontario, Canada

  • Centre Hospitalier Universitaire de Sherbrooke

    Sherbrooke, Quebec, Canada

  • CHC Osijek

    Osijek, Croatia

  • General Hospital Dr. Josip Bencevic

    Slavonski Brod, Croatia

  • CH Dubrava

    Zagreb, Croatia

  • Clinical Hospital Center Zagreb Kispaticeva 12

    Zagreb, Croatia

  • KBC Sestre Milosrdnice

    Zagreb, Croatia

  • KBC Zagreb

    Zagreb, Croatia

  • ICL 6 avenue Bourgogne CS30519

    Vandœuvre-lès-Nancy, France

  • Semmelweis University

    Budapest, Hungary

  • University of Pecs Institute of Oncotherapy

    Pécs, Hungary

  • University of Szeged Dept of Oral and Maxillofacial Surgery

    Szeged, Hungary

  • Markusovsky Teaching Hospital

    Szombathely, Hungary

  • University of Debrecen Medical and Health Scioence Centre

    Debrecen, Hajdú-Bihar, Hungary

  • National institute of Oncology

    Budapest, Rath Gyorgy, Hungary

  • Bibi General Hospital and Cancer Centre

    Malkapet, Andhra Pradesh, India

  • Amrita Institute of Medical Sciences

    Kochi, Kerala, India

  • Sujan Regional Cancer Hospital & Amravati Cancer Foundation

    Amravati, Maharashtra, India

  • Government Medical College and Hospital

    Chhatrapati Sambhajinagar, Maharashtra, India

  • Tata Memorial Hospital

    Mumbai, Maharashtra, India

  • Curie Manavata Cancer Center

    Mumbai, Naka Nashik, India

  • Searoc Cancer Center

    Jaipur, Rajashlan, India

  • V.N. Cancer Center G. Kuppuswamy Naidu Memorial Hospital

    Coimbatore, Tamil Nadu, India

  • Meenakshi Mission Hospital and Research Centre

    Madurai, Tamil Nadu, India

  • Regional Cancer Center

    Kerola, Thiruvananthapuram, India

  • Galaxy Cancer Center

    Ghaziabad, Uttar Pradesh, India

  • Rambam Health Care Campus

    Sha‘ar Ha‘Aliya, Saint Haifa, Israel

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.